Sytze P Rensma1,2, Thomas T van Sloten1,2, Jennifer Ding3, Sigurdur Sigurdsson4, Coen D A Stehouwer1,2, Vilmundur Gudnason4,5, Lenore J Launer6. 1. CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre+, Maastricht, the Netherlands. 2. Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands. 3. Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 4. Icelandic Heart Association, Kópavogur, Iceland. 5. Faculty of Medicine, University of Iceland, Reykjavík, Iceland. 6. Intramural Research Program, Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Baltimore, MD launerl@nia.nih.gov.
Abstract
OBJECTIVE: Type 2 diabetes has been associated with depression. However, the underlying pathophysiological mechanisms remain unknown. Cerebral small vessel disease, a consequence of diabetes, may lead to depression. Therefore, we evaluated whether cerebral small vessel disease mediates the association between type 2 diabetes and higher depressive symptoms. RESEARCH DESIGN AND METHODS: We used longitudinal data from the population-based Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study, with examinations from 2002 to 2006 and 5 years later. Type 2 diabetes was defined as self-reported history of type 2 diabetes, use of blood glucose-lowering drugs, or fasting blood glucose level ≥7.0 mmol/L. Cerebral small vessel disease load was quantified in a composite score based on MRI-defined presence of high white matter hyperintensity volume, low total brain parenchyma volume, and subcortical infarcts, cerebral microbleeds, and large perivascular spaces. The 5-year change in the 15-item Geriatric Depression Scale score (GDS-15) was measured between baseline and follow-up. RESULTS: Included were 2,135 individuals without dementia and baseline depression (baseline age 74.5 [SD 4.6] years, 1,245 women [58.3%], and 197 [9.2%] with diabetes). The GDS-15 score increased 0.4 (SD 1.6) points over time. Baseline diabetes was associated with a greater increase in the GDS-15 score (β = 0.337; 95% CI 0.094; 0.579), adjusted for age, sex, education, and cardiovascular risk factors. Baseline cerebral small vessel disease and change of cerebral small vessel disease statistically significantly mediated a part of this association. CONCLUSIONS: Type 2 diabetes is associated with a greater increase in depressive symptoms score over 5 years, and cerebral small vessel disease partly explains this association.
OBJECTIVE:Type 2 diabetes has been associated with depression. However, the underlying pathophysiological mechanisms remain unknown. Cerebral small vessel disease, a consequence of diabetes, may lead to depression. Therefore, we evaluated whether cerebral small vessel disease mediates the association between type 2 diabetes and higher depressive symptoms. RESEARCH DESIGN AND METHODS: We used longitudinal data from the population-based Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study, with examinations from 2002 to 2006 and 5 years later. Type 2 diabetes was defined as self-reported history of type 2 diabetes, use of blood glucose-lowering drugs, or fasting blood glucose level ≥7.0 mmol/L. Cerebral small vessel disease load was quantified in a composite score based on MRI-defined presence of high white matter hyperintensity volume, low total brain parenchyma volume, and subcortical infarcts, cerebral microbleeds, and large perivascular spaces. The 5-year change in the 15-item Geriatric Depression Scale score (GDS-15) was measured between baseline and follow-up. RESULTS: Included were 2,135 individuals without dementia and baseline depression (baseline age 74.5 [SD 4.6] years, 1,245 women [58.3%], and 197 [9.2%] with diabetes). The GDS-15 score increased 0.4 (SD 1.6) points over time. Baseline diabetes was associated with a greater increase in the GDS-15 score (β = 0.337; 95% CI 0.094; 0.579), adjusted for age, sex, education, and cardiovascular risk factors. Baseline cerebral small vessel disease and change of cerebral small vessel disease statistically significantly mediated a part of this association. CONCLUSIONS:Type 2 diabetes is associated with a greater increase in depressive symptoms score over 5 years, and cerebral small vessel disease partly explains this association.
Authors: Jie Ding; Sigurður Sigurðsson; Pálmi V Jónsson; Gudny Eiriksdottir; Andreas Charidimou; Oscar L Lopez; Mark A van Buchem; Vilmundur Guðnason; Lenore J Launer Journal: JAMA Neurol Date: 2017-09-01 Impact factor: 18.302
Authors: Luis García-Fabela; Efrén Melano-Carranza; Sara Aguilar-Navarro; Juan Miguel Antonio García-Lara; Luis Miguel Gutiérrez-Robledo; José Alberto Avila-Funes Journal: Rev Invest Clin Date: 2009 Jul-Aug Impact factor: 1.451
Authors: Thomas T van Sloten; Sigurdur Sigurdsson; Mark A van Buchem; Caroline L Phillips; Palmi V Jonsson; Jie Ding; Miranda T Schram; Tamara B Harris; Vilmundur Gudnason; Lenore J Launer Journal: Am J Psychiatry Date: 2015-03-03 Impact factor: 18.112
Authors: Guido Lastra; Sofia Syed; L Romayne Kurukulasuriya; Camila Manrique; James R Sowers Journal: Endocrinol Metab Clin North Am Date: 2013-12-12 Impact factor: 4.741
Authors: Ann I Scher; Larus S Gudmundsson; Sigurdur Sigurdsson; Anna Ghambaryan; Thor Aspelund; Gudny Eiriksdottir; Mark A van Buchem; Vilmundur Gudnason; Lenore J Launer Journal: JAMA Date: 2009-06-24 Impact factor: 56.272
Authors: Joanna M Wardlaw; Eric E Smith; Geert J Biessels; Charlotte Cordonnier; Franz Fazekas; Richard Frayne; Richard I Lindley; John T O'Brien; Frederik Barkhof; Oscar R Benavente; Sandra E Black; Carol Brayne; Monique Breteler; Hugues Chabriat; Charles Decarli; Frank-Erik de Leeuw; Fergus Doubal; Marco Duering; Nick C Fox; Steven Greenberg; Vladimir Hachinski; Ingo Kilimann; Vincent Mok; Robert van Oostenbrugge; Leonardo Pantoni; Oliver Speck; Blossom C M Stephan; Stefan Teipel; Anand Viswanathan; David Werring; Christopher Chen; Colin Smith; Mark van Buchem; Bo Norrving; Philip B Gorelick; Martin Dichgans Journal: Lancet Neurol Date: 2013-08 Impact factor: 44.182
Authors: Diana Maria Ariton; Joan Jiménez-Balado; Olga Maisterra; Francesc Pujadas; María José Soler; Pilar Delgado Journal: J Clin Med Date: 2021-05-27 Impact factor: 4.241